5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3'-bipyridine

Catalog No. :
ACUMHZ959
CAS No. :
1260106-29-3
Molecular Formula :
C16H19BN2O2
Molecular Weight :
282.15

IUPAC Name:5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3'-bipyridine

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3'-bipyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3'-bipyridine
IUPAC Name5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3'-bipyridine
MDL No.MFCD12032567
Molecular FormulaC16H19BN2O2
Molecular Weight282.15
SMILESCC1(C)C(C)(C)OB(C2=CN=C(C3=CC=CN=C3)C=C2)O1
InChI KeyGFXQVUCMWYWUIE-UHFFFAOYSA-N
Synonym5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-2,3'-bipyridine;2,3'-Bipyridine, 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.1260106-29-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACUMHZ959 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACPBMH705 route compound structure diagram
    ACPBMH705774-53-8 In Stock
  2. Plus
  3. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  4. Then
  5. ACUMHZ959 route product structure diagram
    ACUMHZ9591260106-29-3
Inquiry

2. ACUMHZ959 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACXIZU058 route compound structure diagram
    ACXIZU058444120-94-9 In Stock
  2. Plus
  3. ACPGVQ689 route compound structure diagram
    ACPGVQ6891692-25-7 In Stock
  4. Then
  5. ACUMHZ959 route product structure diagram
    ACUMHZ9591260106-29-3
Inquiry

Comments (0)